We are pleased to announce the launch of our educational webinar series focussing on the clinical applications of our Freelite assays in different monoclonal gammopathies and neurological disorders, presented by Dr. James Last, Lead International Medical Science Liaison.
Please join us for this exciting monthly series, as scheduled below.
If you missed any of our webinars, you watch them here:
Dr. James Last is the Lead International Medical Science Liaison at The Binding Site, part of Thermo Fisher Scientific. James achieved his undergraduate degree in Molecular Cell Biology at The University of Nottingham, UK before completing his PhD in Cancer Sciences at the University of Birmingham, UK. Following 8 years post-doctoral research, James joined The Binding Site as a Medical Science Liaison in 2013, providing educational seminars on the clinical utility of Binding Site technologies as well as organising national and international trials to evaluate these assays. More recently, James has progressed into his current role managing and coordinating the scientific activities of the International Sales Medical Science Liaison team. In January 2023, Thermo Fisher Scientific purchased The Binding Site and created the Protein Diagnostics unit, as part of the Specialty Diagnostics Group.